ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Addiction · Drug Alcohol Depend · 2026-10-08

In 180 adults who smoked and were switching to e-cigarettes, bupropion-zonisamide did not lower end-of-treatment exhaled CO versus bupropion or placebo (mITT); abstinence was 26.7%, 25.0% and 10.0%. Weight fell with the combination but rose with the others.

RCTn = 180
Rose et al. Combination bupropion-zonisamide facilitates rapid reduction in smoke exposure and prevents weight gain during switching to electronic nicotine delivery systems: A randomized clinical trial
Psychiatry · JAMA Psychiatry · 2026-08-01

Individual participant meta-analysis of 12 placebo-controlled trials (2000 people with cocaine or methamphetamine dependence): pooled medications did not significantly improve reduced use (primary) or urine-verified abstinence; 31.2% vs 13.3% achieved each overall.

Meta-analysisn = 2,000
Amin-Esmaeili et al. Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder: A Meta-Analysis of 12 Randomized Controlled Trials
Addiction · Drug Alcohol Depend · 2026-07-28

Systematic review of 11 RCTs (9 meta-analysed): with non-titratable NRT, normal/fast nicotine metabolisers had lower odds of verified quitting than slow metabolisers (OR 0.81, 95% CI 0.68–0.96); no significant difference with titratable NRT, bupropion or varenicline.

Meta-analysisn = 11 trials
Xie et al. Role of nicotine metabolite ratio in pharmacological interventions on smoking cessation: A systematic review and meta-analyses of randomized controlled trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.